Cellectar Biosciences (CLRB) Change in Accured Expenses (2010 - 2025)

Cellectar Biosciences has reported Change in Accured Expenses for 16 years, with the latest figure at $408866.0 in Q4 2025.

• Quarterly Change in Accured Expenses rose 156.87% year-over-year to $408866.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$3.2 million (down 98.44% YoY) and the FY2025 annual result came in at -$3.2 million, down 98.44% from the prior year.
• Change in Accured Expenses advanced to $408866.0 in Q4 2025 per CLRB's latest filing, from -$664031.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $1.8 million in Q3 2024 and troughed at -$3.7 million in Q1 2025.
• A 5-year average of $49017.6 and a median of $532834.0 in 2022 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 423.48% in 2021, down 666.53% in 2021.
• Over 5 years, Change in Accured Expenses stood at $820425.0 in 2021, then plunged by 208.31% to -$888592.0 in 2022, then jumped by 253.51% to $1.4 million in 2023, then sank by 152.71% to -$718971.0 in 2024, then surged by 156.87% to $408866.0 in 2025.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $408866.0, -$664031.0, and $804284.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.